Sharp Therapeutics Corp. Reports Third Quarter 2025 Results and Development Update

Rhea-AI Summary

Sharp Therapeutics (OTCQB: SHRXF; TSXV: SHRX) released condensed interim consolidated financial statements for the three and nine months ended September 30, 2025 and related MD&A.

The company reported it increased R&D spending by 34% versus the comparable quarter in 2024 to advance its Gaucher, Niemann Pick C and Progranulin programs and is targeting entry into Phase I clinical trials in 2026. Sharp describes itself as a pre-clinical small-molecule therapeutics developer using computationally optimized libraries and high-throughput screening.

Positive

• R&D spend up 34% vs comparable quarter 2024
• Targeting Phase I clinical trial entry in 2026
• Advancing three named programs: Gaucher, Niemann Pick C, Progranulin

Negative

• Company is in a pre-clinical stage; no human trial data yet

News Market Reaction – SHRXF

-41.41%

1 alert

-41.41% News Effect

On the day this news was published, SHRXF declined 41.41%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Q3 R&D spending change: 34% more Target trial phase: Phase I Trial start target year: 2026 +5 more

8 metrics

Q3 R&D spending change 34% more R&D spending vs comparable quarter in 2024

Target trial phase Phase I Planned clinical trials entry in 2026

Trial start target year 2026 Company’s stated goal for entering Phase I trials

Q2 R&D increase 85% increase R&D spending vs Q2 2024 (historical earnings release)

Price vs 52-week high -46.71% Distance from 52-week high before Q3 release

Price vs 52-week low 505.98% Distance from 52-week low before Q3 release

Pre-news price move 10.35% 24h price change prior to this Q3 announcement

Conference reaction 44.97% 24h move after Oct 08, 2025 conference news

Market Reality Check

Price: $1.5800 Vol: Volume 100 vs 20-day aver...

low vol

$1.5800 Last Close

Volume Volume 100 vs 20-day average 4,870 (volume_relative 0.02) indicates very light trading ahead of this update. low

Technical Price at 1.844 is below the 200-day MA of 1.95, with shares also trading 46.71% under the 52-week high.

Peers on Argus

No peer stocks or sector momentum data were flagged, suggesting the pre-news mov...

No peer stocks or sector momentum data were flagged, suggesting the pre-news move in SHRXF (10.35%) appeared stock-specific rather than part of a broader sector trend.

Historical Context

2 past events · Latest: Oct 08 (Positive)

Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
Oct 08	Conference presentation	Positive	+45.0%	Presented preclinical data and pipeline updates at World Orphan Drug Congress 2025.
Aug 29	Earnings & listing	Positive	-0.5%	Reported Q2 results, OTCQB listing, and 85% increase in R&D spending.

Pattern Detected

Limited history shows positive conference news aligned with a strong gain, while an earnings update emphasizing higher R&D and a new listing saw a slight negative reaction.

Recent Company History

Over recent months, Sharp issued an earnings and listing update on Aug 29, 2025 and a conference presentation on Oct 08, 2025. The Q2 earnings/OTCQB listing news highlighted an 85% R&D increase and saw a modest -0.5% move. The World Orphan Drug Congress update, showcasing Phase 1–ready ‘901 data and pipeline progress, coincided with a strong 44.97% gain. Today’s Q3 update continues the theme of elevated R&D spending and progress toward Phase I trials planned for 2026.

Market Pulse Summary

The stock dropped -41.4% in the session following this news. A negative reaction despite continued R...

Analysis

The stock dropped -41.4% in the session following this news. A negative reaction despite continued R&D investment would contrast with the strong 44.97% move after the October 2025 conference but echo the modest -0.5% response to the prior earnings release. The stock traded 46.71% below its 52-week high ahead of this update, suggesting sentiment had not fully recovered. Elevated spending, such as the reported 34% Q3 R&D increase vs 2024, may at times raise concerns about near-term dilution or timelines.

Key Terms

phase i clinical trials, pre-clinical stage, small-molecule therapeutics, high throughput screening, +4 more

8 terms

phase i clinical trials medical

"Our investment will continue as we aim for our next milestone of entering Phase I clinical trials in 2026."

Phase I clinical trials are the first formal tests of a new drug or medical treatment in humans, usually involving a small number of volunteers to evaluate safety, appropriate dose ranges and how the body handles the treatment. For investors, these trials are an early checkpoint: positive safety and dosing results lower development risk and increase a program’s value, while problems can signal delays, higher costs or program failure — like a prototype’s initial safety test.

pre-clinical stage medical

"Sharp Therapeutics is a pre-clinical stage company developing first-choice small-molecule therapeutics for genetic diseases."

A pre-clinical stage is the early phase of developing a drug or medical product when researchers test it in cells, tissues and usually animals to check safety, dosing and whether it does what it’s supposed to before any human trials begin. For investors this is where a project is highest risk but lowest cost: results act like prototype tests that either justify bigger investment and human trials or reveal fatal flaws, affecting future value and timelines.

small-molecule therapeutics medical

"pre-clinical stage company developing first-choice small-molecule therapeutics for genetic diseases."

Small-molecule therapeutics are low-weight chemical drugs designed to enter cells and directly interact with specific proteins or pathways, like tiny keys that fit into biological locks to change how a cell works. They matter to investors because they often can be taken orally, manufactured at scale more cheaply than larger biologic drugs, and follow well-established regulatory paths, which influences development risk, time to market and production costs.

high throughput screening technical

"discovery platform combines novel high throughput screening technologies, with compound libraries computational optimized..."

High throughput screening is a laboratory method that rapidly tests thousands to millions of chemical or biological samples to find ones that affect a chosen biological target, like a protein linked to disease. For investors, it matters because it speeds early-stage drug or product discovery, helps identify promising candidates faster and more cheaply, and can increase the chances a development program yields a viable product — like using automated sorting to find the few needles in a very large haystack.

compound libraries technical

"high throughput screening technologies, with compound libraries computational optimized based on the physics and biology..."

A compound library is a curated collection of chemical or biological molecules that scientists test to find candidates that affect a disease target — think of it as a company’s toolbox or catalog of potential keys to fit a medical lock. For investors, the size, diversity and quality of a compound library indicate a research organization’s ability to discover new drugs, speed up development, attract partners or generate licensing revenue, so it helps gauge future pipeline value and technological edge.

allosteric activation medical

"cellular trafficking defects and allosteric activation of proteins."

Allosteric activation is when a small molecule binds to a spot on a protein that is not the main active site and changes the protein’s shape so it works better or more often. For investors, this matters because allosteric activators can make drugs more selective and safer, open up new targets that were hard to treat before, and create distinct intellectual property and commercial opportunities compared with conventional drugs.

lysosomal enzyme medical

"designed to restore lysosomal enzyme function with potential to treat peripheral and CNS manifestations..."

Lysosomal enzymes are proteins that act like a cell’s recycling crew, breaking down worn-out parts, fats, sugars, and other waste inside small compartments called lysosomes so the cell can reuse or dispose of them. For investors, they matter because defects or shortages in these enzymes cause genetic diseases and are targets for diagnostics, enzyme replacement therapies, and other treatments—areas that can drive drug development, regulatory risk, manufacturing complexity, and potential market value.

genetic diseases medical

"First-Choice Therapies for Genetic Diseases Sharp Therapeutics is a pre-clinical stage company..."

Genetic diseases are health conditions caused by changes or errors in a person’s DNA that are inherited or arise spontaneously, like a faulty instruction in a recipe that makes the final dish wrong. For investors, they matter because treatments, diagnostics, and screening for these conditions can drive long-term revenue, affect regulatory approvals, and create high-risk, high-reward opportunities in biotech and healthcare markets.

AI-generated analysis. Not financial advice.

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - November 26, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), announces the release of its condensed interim consolidated financial statements for the three and nine months ended September 30, 2025, and related management discussion and analysis. All dollar figures are in United States dollars, unless otherwise stated.

Scott Sneddon, Sharp's Chief Executive Officer, stated: "Our Q3 financial results show our continued investment in research and development programs, mainly our Gaucher, Niemann Pick C and Progranulin programs. We spent 34% more than the comparable quarter in 2024 which continues to move the Company towards Phase I clinical trials. Our investment will continue as we aim for our next milestone of entering Phase I clinical trials in 2026."

About Sharp Therapeutics Corp.

First-Choice Therapies for Genetic Diseases

Sharp Therapeutics is a pre-clinical stage company developing first-choice small-molecule therapeutics for genetic diseases. The Company's discovery platform combines novel high throughput screening technologies, with compound libraries computational optimized based on the physics and biology of cellular trafficking defects and allosteric activation of proteins. The platform produces small molecule compounds that restore activity in mutated proteins giving the potential to treat genetic disorders with conventional pill-based medicines.

For additional information on Sharp, please visit: www.sharptx.com.

Sharp Therapeutics Corp.
Scott Sneddon, PhD, JD 
CEO/CSO
Email: scott@sharptx.com

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect Sharp's current views and intentions with respect to future events, and current information available to Sharp, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Should any factor affect Sharp in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Sharp does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and Sharp undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276020

FAQ

What did Sharp Therapeutics (SHRXF) report for the quarter ended September 30, 2025?

Sharp released condensed interim consolidated financial statements and MD&A for the three and nine months ended September 30, 2025.

How much did Sharp (SHRXF) increase R&D spending in Q3 2025?

Sharp reported R&D spending was 34% higher than the comparable quarter in 2024.

Which programs is Sharp Therapeutics (SHRXF) advancing toward clinical trials?

Sharp is advancing its Gaucher, Niemann Pick C, and Progranulin small-molecule programs.

When does Sharp (SHRXF) expect to enter Phase I clinical trials?

The company is aiming to enter Phase I clinical trials in 2026.

What stage is Sharp Therapeutics (SHRXF) in its development pipeline?

Sharp is a pre-clinical stage company developing small-molecule therapies; no human trial readouts yet.